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Abstract
Background:  Smear-negative pulmonary tuberculosis (TB) accounts for a considerable proportion of TB
transmission, which especially endangers health care workers (HCW). Novel Mycobacterium-tuberculosis-
specific interferon-γ release assays (IGRAs) may offer the chance to define the burden of TB in HCW more
accurately than the Mantoux tuberculin skin test (TST), but the data that is available regarding their performance
in tracing smear-negative TB in the low-incidence, in-hospital setting, is limited. We conducted a large-scale, in-
hospital contact investigation among HCW of a German university hospital after exposure to a single case of
extensive smear-negative, culture-positive TB with pulmonary involvement. The objective of the present study
was to evaluate an IGRA in comparison to the TST and to identify risk factors for test positivity.
Methods:  Contacts were prospectively enrolled, evaluated using a standardized questionnaire, the IGRA
QuantiFERON®-TB Gold in Tube (QFT-GIT) and the TST, and followed-up for two years. Active TB was ruled
out by chest x-ray in QFT-GIT-positive subjects. Independent predictors of test positivity were established
through the use of logistic regression analysis.
Results: Out of the 143 subjects analyzed, 82 (57.3%) had close contact, but only four (2.8%) experienced
cumulative exposure to the index case >40 hours. QFT-GIT results were positive in 13 subjects (9.1%), while TST
results were positive in 40 subjects (28.0%) at an induration >5 mm. Overall agreement was poor between both
tests (kappa = 0.15). Age was the only predictor of QFT-GIT-positivity (Odds ratio 2.7, 95% confidence interval
1.32–5.46), while TST-positivity was significantly related to Bacillus Calmette-Guérin vaccination and foreign
origin. Logistic regression analysis showed no relation between test results and exposure. No secondary cases of
active TB were detected over an observational period of two years.
Conclusion: Our findings suggest a low contagiosity of the particular index case. The frequency of positive QFT-
GIT results may in fact reflect the pre-existing prevalence of latent TB infection among the study population. TB
transmission seems unlikely and contact tracing not generally warranted after cumulative exposure <40 hours.
However, the substantially lower frequency of positive QFT-GIT results compared to the TST may contribute to
enhanced TB control in health care.
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Background
Tuberculosis (TB) is a major cause of illness and death
worldwide [1]. In contrast, Germany is a low-incidence
country with steadily decreasing annual numbers of new
TB infections (6.1 per 100,000 inhabitants in 2007) [2],
where targeted testing of at-risk groups as well as diagno-
sis and treatment of latent TB infection (LTBI) in individ-
uals with recent exposure are fundamental components of
TB control strategies [3].
Although cross-reactivity following vaccination with
Bacillus Calmette-Guérin (BCG) or exposure to non-
tuberculous mycobacteria is common, the tuberculin skin
test (TST) has been applied for the diagnosis of LTBI for
about a century [4]. In-vitro interferon-γ release assays
(IGRAs) that measure the amount of interferon-(IFN)-γ
secreted by T-cell lymphocytes after stimulation with
highly Mycobacterium-tuberculosis-(MTB)-specific anti-
gens have been developed as alternative diagnostics. They
are broadly recommended and increasingly used in con-
tact investigations [5,6], as they provide distinct advan-
tages over the TST. Their sensitivity for detecting active TB,
which is commonly used as a surrogate for LTBI, is at least
equal and their specificity is clearly superior, at least in
populations that contain a proportion of BCG-vaccinated
individuals, as they are not confounded by BCG vaccina-
tion. Moreover, they are appropriate for the serial testing
of health care workers (HCW) as they avoid boosting of
immune responses and possess distinct logistical conven-
iences [7-9].
Acid-fast bacilli smear-negative, culture-positive pulmo-
nary TB accounts for a considerable proportion of TB
transmission. In 2007, 56.3% of all infectious pulmonary
TB cases reported to the responsible German authority
(Robert Koch Institute) were smear-negative [2]. Although
in general considered less contagious, smear-negative TB
index cases were found to be responsible for 13–17% of
TB transmission in molecular-epidemiologic studies
[10,11]. The characteristics of smear-negative TB cases
include prolonged contact, lack of isolation and delayed
diagnosis and treatment, thus highlighting its impact as a
nosocomial disease and its importance to TB control in
high-income, low-incidence countries and health care.
TB contact investigations in the in-hospital setting are
often challenging due to patient movement and the
changing work assignment of personnel [12]. Particularly
HCW are considered at risk for the occupational transmis-
sion of TB infection, even after brief exposure [13,14]. In
this regard, IGRAs may offer the unique chance of defin-
ing the burden of TB in HCW more accurately [15].
We conducted an in-hospital contact investigation of a
single index patient with extensive smear-negative, cul-
ture-positive TB including non-cavitary pulmonary
involvement, who had a complicated in-hospital course
of about three months and numerous contacts in various
medical departments and disciplines (Figure 1, also see
additional file 1: Definition of the index case). The aim of
the present study was to compare the performance of the
IGRA QuantiFERON®-TB Gold in Tube (QFT-GIT) with
the Mantoux tuberculin skin test (TST) in a large-scale in-
hospital contact investigation among German HCW after
exposure to a single case of smear-negative, culture-posi-
tive pulmonary TB and to identify independent risk fac-
tors of test positivity.
Methods
Study design and subjects
We prospectively enrolled eligible HCW. The suspected
time of in-hospital infectivity was 57 days from referral to
our neurotraumatological department on January 10th
until March 7th 2007, when isolation and antimycobacte-
rial treatment were initiated. Contacts were evaluated
using a standardized interview and questionnaire, TST,
IGRA and chest x-ray if IGRA results were positive. The
diagnostic and therapeutic course of the index case
throughout the entire hospital stay was reconstructed. A
total of 202 HCW with suspected contact were reported to
the responsible occupational physician. Inclusion criteria
were an age of 18 years and above, actual contact to the
index case during infectivity and written and informed
consent. The study cohort was longitudinally observed
regarding progression to active TB for a period of two
years (mean 106 ± 1.5 weeks) until March 13th 2009. All
HCW were informed of TB-related symptoms, instructed
on self-monitoring and reporting and subject to routine
follow-up screening according to German Occupational
Safety and Health legislation. All QFT-GIT-positive sub-
jects were radiologically followed up as recommended by
national guidelines [6].
Diagnostic methods
The TST was performed by the Mantoux method using 0.1
ml (two tuberculin units) of purified protein derivative
(PPD) RT 23 (Statens Serum Institute, Copenhagen, Den-
mark). The test was administered strictly intradermally to
the volar side of the forearm and was read 72 hours after
application. The transverse diameter of induration was
measured and documented as described previously [16].
A diameter of >5 mm was considered positive according
to national guidelines [6]. Both the administration and
the reading of the TST were performed by the same expe-
rienced occupational physician in order to minimize
observer-dependent variation.
As an IGRA, the QFT-GIT (Cellestis, Carnegie, Australia)
was used. ELISAs and the interpretation of QFT-GIT
results were performed according to the manufacturer'sJournal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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Study profile Figure 1
Study profile. HCW = health care workers; IGRA = interferon-γ release assay. PCT = preventive chemotherapy; PPD = puri-
fied protein derivate; QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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instructions that consider a result positive if the IFN-γ
response of TB antigen minus Nil was ≥ 0.35 IU/ml (see
additional file 2: Addendum methods section). All assays
met quality control standards. The occupational physician
who read the TST was blinded to the QFT-GIT results
determined by the laboratory team and vice versa. In par-
ticipants with positive QFT-GIT results, active TB was
ruled out by physical examination and chest x-ray, and the
subsequent administration of preventive chemotherapy
with Isoniazid (INH) for nine month was suggested fol-
lowing current national and international recommenda-
tions [3,6].
Interview and questionnaire items
A standardized interview was conducted by the occupa-
tional physician. A questionnaire as well as medical
records were used for the collection of demographic and
clinical data with special attention paid to established
individual risk factors regarding the acquisition of a new
TB infection, the reactivation of LTBI or false negative or
false positive TST results (see additional file 2: Addendum
methods section) [3,6]. BCG vaccination status was reas-
sured by medical and vaccination records or the presence
of vaccination scars.
Evaluation of exposure
Close contact and thus a relevant risk of transmission even
after short exposure was assumed if there was exposure
during airway management, transesophageal echocardi-
ography, gastroscopy or face-to-face contact during a
physical examination, physiotherapy or patient care and
nursing (e. g. oral hygiene, patient transfer) [6]. The
cumulative exposure time was calculated according to
Arend et al. [17]: the contact period in weeks, the average
number of days per week on which there had been con-
tact, the number of contacts per shift according to work
assignment and the average contact time (min) were mul-
tiplied and resulted in the cumulative exposure time
(min). In order to achieve a maximum accuracy, special
attention was paid both to the index patient's course
throughout the different medical departments, and to the
work assignments and working schedules of the HCW.
Statistical analysis
Data analysis was performed using SPSS, version 11.5
(SPSS Inc., Chicago, Illinois). Categorical data were com-
pared by Pearson's chi-squared or Fisher's exact test,
where appropriate. Normal distribution in continuous
variables was determined with the Kolmogorov-Smirnov
test and differences were subsequently determined either
with the student's t-test or the Mann-Whitney-U test.
Spearman correlation coefficients and kappa values were
calculated for both tests. Relations were described as odds
ratio (OR) and 95% confidence interval (CI). ORs for test
results depending on different putative predictive varia-
bles were calculated using logistic regression. Model
building was performed backwards using the chance crite-
ria for variable selection [18]. All p values reported were
calculated two-sided with statistical significance set to p <
0.05. The study protocol was approved by the ethics com-
mittee of the Ruhr-University, Bochum. All study partici-
pants gave their written and informed consent.
Results
Study population
Between June and August 2007, mean 17 ± 2 weeks after
last exposure to the source case, 202 HCW with suspected
contact were evaluated. Of those, 44 had not had contact
or had not been exposed during the time of infectivity. Of
the 158 eligible contacts, 14 denied consent and 144 were
recruited for the study. One subject (with a negative TST
result) was excluded from data analysis due to an indeter-
minate QFT-GIT result (see additional file 3: Detailed
description of the subject with indeterminate QFT-GIT
result). Finally, 143 of the 158 eligible contacts (90.5%)
constituted the study population (Figure 1). The demo-
graphic and clinical features of the study population are
shown in Table 1. The HCWs' different affiliations and
professions are displayed in Figure 1. The present popula-
tion was characterized by a mean age of 38 ± 10 years
(range 20–62) and a mean duration of employment in
health care of 14 ± 10 years (range 1–42). As these varia-
bles were highly correlated (r = 0.72, p < 0.001), the latter
was not considered for the logistic regression analysis.
More than one half of the subjects were BCG vaccinated
(51.0%), while only a small number of subjects had been
born in a high endemic TB country (2.8%).
None of the contacts reported seropositivity for HIV. Hep-
atitis C virus infection and immunosuppressive treatment
were reported by one single subject each. Neither smoking
habits, alcohol consumption, comorbidity, travelling to
TB high burden countries within the past 12 months nor
the presence of unspecific symptoms was associated with
the test results in univariate or multivariate analysis (data
not shown).
Exposure to the source case
The median cumulative exposure time was 60 min and
ranged from 3 to 4000 min (67 h). Eighty two subjects
(57.3%) had had close contact to the index case. These
included four individuals (2.8%), who had been exposed
for >40 hours (Table 1). The cumulative exposure time
correlated well with close contact to the index case (r =
0.54, p < 0.001).
Interferon-γ release assay results
QFT-GIT results were positive in 13 of the 143 contacts
(9.1%). The QFT-GIT-positive subjects were significantly
older (mean age [± standard deviation] 46 ± 10 vs. 37 ± 9Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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yrs, p = 0.006) and had been working in health care for a
longer period of time than the QFT-GIT-negative subjects
(mean 21 ± 12 vs. 12 ± 8 yrs, p = 0.032). However, there
was no difference between median cumulative exposure
times with regard to the QFT-GIT results (20 vs. 60 min,
range 6 to 2625 min [44 h] vs. 3 to 4000 min [67 h], p =
0.31). Remarkably, the only subject with a history of prior
TB in 1976 had a negative QFT-GIT (IFN 0.046 IU/ml),
but a positive TST result (15 mm induration). Figure 2
shows positivity rates for the overall performance and the
variables age (categorized), foreign origin and BCG vacci-
nation status according to the diagnostic method and the
TST cut-off applied. There was a trend towards higher
QFT-GIT positivity rates with increasing TST induration
(5.8%, 8.3%, 16.7% and 25.0% for induration categories
0–5 mm, 6–10 mm, 11–15 mm and >15 mm, respec-
tively; p = 0.070; Figure 3).
Tuberculin skin test results
The TST was read mean 72 ± 5 hours after application.
Overall, 40 contacts (28.0%) and 28 contacts (19.6%)
had a positive TST result when a cut-off >5 mm and >10
mm induration was applied, respectively. Mean age rather
than mean duration of employment in health care, was
significantly higher in TST-positive subjects when com-
pared to TST-negative subjects (mean age 40 ± 9 vs. 36 ± 9
yrs and 41 ± 9 vs. 37 ± 10 yrs, p = 0.036 and 0.038, respec-
tively; mean duration of employment in health care 15 ±
10 vs. 13 ± 8 yrs and 16 ± 10 vs. 13 ± 9 yrs, p = 0.25 and
0.14, respectively). Whichever TST cutoff was applied,
there was no difference between the median cumulative
exposure times (both 60 minutes, ranges 5 to 2520 min
[42 h] vs. 3 to 4000 min [67 h], p = 0.48 and 0.85, respec-
tively).
Concordance between QFT-GIT and TST results and effect 
of BCG vaccination
More than one half of the contacts (51%) were BCG vac-
cinated (Table 1). Table 2 shows the agreement between
QFT-GIT and TST results stratified according to the BCG
vaccination status. The overall agreement between TST
and QFT-GIT results was low when a cutoff >5 mm was
applied and was only slightly higher for a cutoff >10 mm.
With regard to those individuals who had not been BCG
vaccinated, a better, but nevertheless low agreement was
observed regardless of the applied cut-off. In total, con-
cordant results between QFT-GIT and recent Mantoux TST
results occurred in 72.7% of the subjects (104/143), pre-
dominantly in those with negative results in both tests
(97/104, 93.3%) when a TST cutoff >5 mm was used. Dis-
cordant test results were observed in 27.3% of the subjects
(39/143), most of them in the combination TST-positive/
IGRA-negative (33/39, 84.6%; overall frequency 23.1%,
33/143), which was significantly associated with BCG vac-
cination (p = 0.020). An unknown BCG vaccination status
was significantly associated with foreign origin (40% vs.
3.4% of subjects, p < 0.001). Data on BCG vaccination sta-
tus was completely documented in individuals of Polish
origin only (77.8% BCG vaccinated).
Comparison of current test results with prior TST results
One hundred and seventeen subjects (81.8%) had been
tested with a prior TST median five years (range 3 mo to
38 yrs) ago. In most instances, prior TST had been admin-
istered by the multi-puncture method (92.3%, 108/117).
Of those, 38.5% had had a positive prior TST result (Table
1). Positivity rates of prior TST results in relation to age,
Table 1: Characteristics of the study population
Variables n %
Subjects, total 143 100
Sex
Male 44 30.8
Female 99 69.2
Age categorized*
18 to 39 years 84 58.7
40 to 49 years 36 25.2
≥ 50 years 23 16.1
Duration of employment in health care*
1 to 5 years 35 24.5
6 to 10 years 25 17.5
11 to 20 years 50 35.0
21 to 42 years 33 23.1
Foreign country of birth†
Yes 25 17.5
No 118 82.5
Birth in high burden country‡ 42 . 8
BCG vaccination
Yes 73 51.0
No 56 39.2
unknown 14 9.8
Cumulative exposure time
≤ 1 hour 76 53.1
> 1 to 8 hours 42 29.4
> 8 to 40 hours 21 14.7
> 40 hours 4 2.8
Close contact 82 57.3
Prior TST 117 81.8
Positive prior TST result 45 38.5
TST >5 mm induration 40 28.0
TST >10 mm induration 28 19.6
Positive QFT-GIT result 13 9.1
Health care professions
Nursing 49 34.3
Physician 24 16.8
Other 70 49.0
Affiliation with Pulmonary Care 18 12.6
Own history of TB 1 0.7
Family history of TB 8 5.6
* Age and duration of employment were highly correlated (r = 0.72, p 
< 0.001). † Mostly Poland (n = 9) and Turkey (n = 7). ‡ TB high burden 
countries (according to WHO [1]): Morocco (n = 2), Philippines (n = 
1), Bosnia and Herzegovina (n = 1). BCG = Bacillus Calmette-Guérin; 
TB = tuberculosis; TST = tuberculin skin test.Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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foreign origin and BCG vaccination status are shown in
Figure 2 to provide a comparison with current test results.
Prior TST results showed low overall agreement with
recent Mantoux TST results (kappa = 0.38 and kappa =
0.32, p < 0.001 each, for an induration >5 mm and >10
mm, respectively), low overall agreement with QFT-GIT
results (kappa = 0.09, p = 0.18) and low agreement with
QFT-GIT even in non-BGC vaccinated subjects (kappa =
0.30, p = 0.077).
Independent predictors of test positivity
Multiple logistic regression analysis confirmed the age
dependency of positive QFT-GIT results (Table 3). The
chance of having a positive QFT-GIT result increased
about threefold with age (using three age categories, OR
2.7, 95% CI 1.32–5.46). However, no relation with BCG
vaccination, foreign origin, exposure time per hour, close
contact or any other variable was observed. Moreover,
both foreign origin and BCG vaccination increased the
probability of having a positive TST result about three-
and fourfold depending on the respective cut-off applied.
Again, no link to exposure (or family history of TB) was
observed for the TST (Table 3).
Clinical impact of QFT-GIT test results and follow-up
Active TB was ruled out by physical examination and chest
x-ray in all 13 participants with positive QFT-GIT results.
Consultation and INH preventive therapy was offered to
QFT-GIT-positive contacts only. Remarkably, only one
QFT-GIT-positive HCW (7.7%) administered preventive
therapy with INH as recommended. None of the contacts
developed active TB within a period of two years (106 ±
1.5 weeks) after the last exposure to the index case.
Discussion
The QFT-GIT proved to be feasible for contact tracing
HCW in a low TB incidence in-hospital setting containing
a high proportion of BCG vaccinated individuals even in
a smear-negative index case. No secondary cases of active
TB were detected within the observational period of two
years, and the positive test results were not related to
exposure. Altogether, relevant nosocomial TB transmis-
sion appears unlikely. The frequency of positive QFT-GIT
results may in fact reflect the pre-existing prevalence of
LTBI in the study population. Thus, IGRAs may offer the
chance to increase the accuracy of diagnosing LTBI,
enhance the implementation of preventive chemotherapy
and further improve TB control in low-incidence coun-
tries and health care.
Comparison with previous literature in the field
We determined a low overall frequency of positive QFT-
GIT results of 9.1%. This frequency was substantially
lower compared with the recent Mantoux TST (28.0%) or
to the prior TST (38.5%). These findings are in agreement
with studies on comparable populations determining the
prevalence of LTBI among HCW without recent TB expo-
sure. Just about one decade ago, Kralj and colleagues pro-
posed a LTBI prevalence among German HCW of 40%
according to positive multi-puncture TST results [19].
More recently, Nienhaus and Schablon and colleagues
reported QFT-GIT positivity rates between 7.2–12.4%
among German HCW [20-22]. In a Swiss study of HCW at
a university hospital, a frequency of 7.6% was reported
[23]. Similarly, Harada and colleagues concluded a LTBI
prevalence of 9.9% among HCW in an intermediate-inci-
dence country (Japan) using an earlier version of the
Frequencies of positive test results Figure 2
Frequencies of positive test results. Frequencies of recent positive test results (%) are displayed depending on: A) overall 
positivity; B) categorized age; C) birth in a foreign country; D) Bacillus Calmette-Guérin (BCG) vaccination. Prior TST results 
are plotted for comparison (dark blue column).Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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QuantiFERON®-TB Gold assay [24]. A recent Australian
study found results comparable to ours with regard to
QFT-GIT and TST positivity (6.7% vs. 33.0%) and little
agreement between both tests [25]. In contrast, three stud-
ies carried out among Japanese and Danish HCW and
German radiologists detected even lower IGRA positivity
rates of 3% and 1% respectively [26-28].
An informative comparison between the frequencies of
positive IGRA results among the study population of
HCW and the general German population is hampered by
the lack of sufficient data on background IGRA positivity
rates and the fact that the IGRA results depend to a great
extent on the characteristics of exposure, the different set-
tings and populations the test is applied to. Two recent
contact studies that were conducted at an urban public
health department among a population of non-HCW
found QFT-GIT positivity rates of 10% and 11%, respec-
tively, but included recent contacts of smear-positive
index cases with extensive exposure >40 hours only
[29,30]. Moreover, they contained a significantly higher
proportion of foreign-born subjects of 27% and 30%,
respectively, than observed in our study (18%). Another
very recent IGRA contact investigation with a comparable
epidemiologic setting and a major proportion of contacts
of smear-negative source cases (48%) observed an overall
QFT-GIT positivity rate of 24% (92/392) among the con-
tacts of smear-negative source cases [31]. Remarkably, this
study included contacts with positive TST results >5 mm
induration only, more than half of the study population
(52%) were foreign-born, and 55% of the contacts to
smear-negative source cases had an aggregated exposure
time >40 hours. However, the frequency of positive QFT-
GIT results among the contacts of smear-negative source
cases in the subgroup with an exposure time ≥ 40 hours
was only 5% (9/176) compared to 9% (12/139) within
the same subgroup in our study (data not shown). This
observation may indicate a higher QFT-GIT positivity rate
among HCW compared to the general population and
may reflect an increased risk of TB infection among HCW
[13,14].
Moreover, we found a low level of overall agreement
between TST and QFT-GIT results. This finding is consist-
ent with previous studies in HCW and thus confirms that
the BCG vaccination is a major confounder of TST results,
while QFT-GIT results were not affected by BCG
[25,32,33]. Discordant results were frequently observed
and occurred in 27.3% of the subjects with an overall fre-
quency of 23.1% TST-positive/QFT-GIT-negative results.
These findings support data provided by a recent meta-
analysis that reported frequencies of 29.2% for overall dis-
cordant results and 24.1% for TST-positive/QFT-GIT-neg-
ative results, respectively [7].
Logistic regression analysis showed no obvious relation
between exposure and positive results for either of the
applied tests. Instead, we found age to be the only inde-
pendent predictor of QFT-GIT positivity and demon-
strated a further link between foreign origin, BCG
vaccination and positive TST results. In previous contact
tracing studies of profoundly contagious smear-positive
pulmonary TB index cases, IGRA-positivity was well corre-
lated with exposure [15,17,30]. In contrary, studies per-
formed in low- and intermediate-incidence settings
focusing on the prevalence of LTBI among HCW found
age to be closely related to positive IGRA results
[21,22,24].
We detected no secondary cases of active TB within a fol-
low-up period of two years after the last exposure.
Recently, first evidence for the relevance of positive QFT-
GIT results was provided demonstrating a progression rate
to active TB of 14.6% (6/41 subjects) over a two-year
period in subjects who tested positive. However, this
study only included subjects after recent exposure to
smear-positive pulmonary TB >40 hours [30]. Another
study found a progression rate of 8.1% (3/37) among
HIV-1-infected subjects who were routinely screened for
LTBI [34]. To date there are no studies available describing
the predictive value of a single positive QFT-GIT result in
absence of recent and profound smear-positive exposure
or immunosuppression.
Performance of the QFT-GIT in relation to Mantoux TST  results. QFT-GIT = QuantiFERON®-TB Gold in Tube; TST =  tuberculin skin test Figure 3
Performance of the QFT-GIT in relation to Mantoux 
TST results. QFT-GIT = QuantiFERON®-TB Gold in Tube; 
TST = tuberculin skin test.Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
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Limitations
The present study is subject to limitations. Although only
82 HCW (57.3% of the study population, including four
individuals with a cumulative exposure time >40 hours)
had had close contact, all eligible subjects were included
in this contact investigation contrary to current German
and CDC guidelines and assigned to the medium to high
priority category [6,35]. This pre-selection process may
have reduced the pretest probability and subsequently the
efficiency of the procedure. However, TB transmission is
not necessarily correlated with the duration of contact,
and the selection of contacts for screening should also be
activity-based [36,37]. Nevertheless, given the unusual
case presentation, the availability of sufficient resources
and sparse evidence about the performance of IGRAs in
the low-incidence in-hospital setting, we chose to include
all eligible contacts of the particular index case.
Moreover, as there is no gold standard for the diagnosis of
LTBI, both IGRAs and TST tend to indicate the lasting
immune response after exposure to MTB rather than prove
a genuine TB infection [38]. Despite the IGRAs' excellent
specificity, the sensitivity of both QFT-GIT and TST is sub-
optimal at around 70%, and none of these tests is able to
sufficiently discriminate between active disease and latent
infection or between a recently acquired and a prior latent
infection [9,33]. Most studies included in a recent, com-
prehensive meta-analysis used active TB as a surrogate for
Table 2: Agreement between QFT-GIT and TST, stratified by BCG vaccination status
QFT-GIT, n (%)
TST >5 mm Positive Negative Agreement
All subjects Positive 7 (4.9) 33 (23.1) Raw = 72.7%
Negative 6 (4.2) 97 (67.8) κ = 0.15
BCG vaccinated Positive 3 (4.1) 22 (30.1) Raw = 64.4%
Negative 4 (5.5) 44 (60.3) κ = 0.04
No BCG Positive 3 (5.4) 7 (12.5) Raw = 85.8%
Negative 1 (1.8) 45 (80.4) κ = 0.36
TST >10 mm Positive Negative Agreement
All subjects Positive 7 (4.9) 22 (15.4) Raw = 79.7%
Negative 6 (4.2) 108 (75.5) κ = 0.19
BCG vaccinated Positive 3 (4.1) 15 (20.5) Raw = 74.0%
Negative 4 (5.5) 51 (69.9) κ = 0.12
No BCG Positive 2 (3.6) 3 (5.4) Raw = 91.1%
Negative 2 (3.6) 49 (87.5) κ = 0.40
Kappa (κ) values with statistically significant p values are printed bold. P values for TST >5 mm: All subjects, p = 0.048; BCG vaccinated, p = 0.69; 
no BCG, p = 0.016. P values for TST >10 mm: All subjects, p = 0.021; BCG vaccinated, p = 0.35; No BCG, p = 0.036. BCG = Bacillus Calmette-
Guérin; QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.
Table 3: Multiple logistic regression analysis for positive TST and QFT-GIT results
QFT-GIT ≥ 0.35 IU/ml TST > 5 mm TST > 10 mm
Variables Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI)
Male sex 1.0 (0.27–3.51) 1.1 (0.48–2.61) 1.5 (0.56–3.89)
Age categorized* 2.7 (1.32–5.46)# 1.6 (1.00–2.69)# 1.6 (0.90–2.82)#
Foreign birth country 2.5 (0.67–9.42) 3.0 (1.03–8.99)# 4.4 (1.35–14.36)#
BCG vaccination 1.7 (0.44–6.36) 2.9 (1.19–6.86)# 4.2 (1.38–12.85)#
Unknown BCG status 2.4 (0.36–16.20) 1.4 (0.31–6.32)# 2.6 (0.51–13.33)#
Exposure per hour 1.0 (0.95–1.07) 1.0 (0.93–1.02) 1.0 (0.95–1.04)
Close contact 0.7 (0.22–2.41) 1.0 (0.45–2.26) 2.0 (0.74–5.29)
Nursing profession/Physician 1.4 (0.44–4.75) 0.7 (0.31–1.54) 0.7 (0.30–1.83)
Affiliation with Pulmonary Care 0.8 (0.09–6.76) 0.5 (0.14–2.04) 0.5 (0.09–2.50)
Family history of TB 2.9 (0.46–18.01) 3.8 (0.83–17.63) 2.0 (0.40–10.16)
* Compare Table 1. # Variable included in final model building. OR and 95% CI with statistical significance are printed bold. BCG = Bacillus 
Calmette-Guérin; CI = confidence interval; OR = Odds ratio; QFT-GIT = QuantiFERON®-TB Gold in tube; TST = tuberculin skin test.Journal of Occupational Medicine and Toxicology 2009, 4:11 http://www.occup-med.com/content/4/1/11
Page 9 of 11
(page number not for citation purposes)
the evaluation of sensitivity and specificity, although the
phenomenon of anergy is well known in active TB [9].
Hence, the IGRA responses of patients with active disease
may not be representative of the condition of LTBI as
exemplified by our index patient, who had a clearly nega-
tive QFT-GIT result (IFN 0.189 IU/ml) whilst suffering
from severe active TB. Furthermore, according to national
guidelines, we chose to x-ray QFT-GIT-positive subjects
only, although no data sufficiently proves the superiority
of the QFT-GIT in respect of sensitivity for detecting LTBI
or active TB. In fact, this limitation may be emphasized by
the particular HCW with the documented history of TB,
who had a negative QFT-GIT result but a positive TST. In
this context it should be noted that IGRA-negative con-
tacts progressing to active TB have been reported [39,40],
and therefore negative IGRA results should be interpreted
with some caution.
Interpretation of findings
The finding of age-dependency of positive QFT-GIT
results may be due to an age-cohort effect based on stead-
ily decreasing TB-incidence rates in Germany over the past
decades and, on the other hand, to a longer time at risk
whilst being employed in health care. This suggests that a
significant proportion of the QFT-GIT-positive results
were caused by prior MTB infection and not by recent
exposure. Hence, our findings suggest a low contagiosity
of the particular index case. Consequently, the frequency
of positive QFT-GIT results may in fact reflect the pre-
existing prevalence of LTBI among the study population
and makes any relevant nosocomial transmission
unlikely. The observed link between foreign origin and
TST positivity may be due to the proportion of subjects
with unknown BCG vaccination status among the sub-
group of foreign born subjects, and may indicate substan-
tially different BCG vaccination policies among countries
in the past, as documented for Europe [41].
Clinical relevance of findings
The QFT-GIT proved to be a feasible method in this large-
scale, in-hospital contact investigation. Substantially
lower prevalence rates of presumed LTBI resulted when
different approaches of conducting contact investigations
were employed, particularly compared with those that
had been applied in the past (57.3%, 38.5%, 28.0%,
19.6% and 9.1% for a classification by close contact
resulting in chest x-ray, prior TST, recent Mantoux TST
with indurations >5 mm and >10 mm and QFT-GIT,
respectively). This indicates that IGRAs have the potential
to profoundly change our clinical practice. The high fre-
quency of discordant results observed in our study argues
against a two-step screening procedure in a low-incidence
country with a substantial proportion of BCG vaccinated
subjects. Moreover, our results support a recent study by
Diel and colleagues, who suggested the feasibility of
IGRAs in contact investigations of smear-negative index
cases and, in this context, an exposure-dependent per-
formance with markedly increased positivity rates only
after exposure >40 hours [31]. Finally, since the conse-
quently lower number of positive IGRA results offer the
hypothetical chance to target preventive therapy, we will
need to increase the poor acceptance of preventive therapy
apparent in our study. In need of striking arguments, fur-
ther research is necessary on the performance and predic-
tive values of IGRAs in different settings and populations
and on their dynamics over time [39,42].
Conclusion
We did not detect any secondary case of active TB within
the observational period of two years. Overall, the proba-
bility of relevant nosocomial transmission for the particu-
lar index case appears to be low. Our findings suggest that
contact tracing is not generally warranted after cumulative
exposure <40 hours if the index case is smear-negative.
However, given the sensitivities of current IGRAs, they
may not be used to sufficiently rule out the presence of
LTBI. So far, no conclusive statement regarding the pro-
gression risk to active disease in our population and par-
ticular setting can be made. Both IGRAs and TST possess
inherent limitations, and lack the ability to reliably dis-
criminate between recently acquired or prior latent TB
infection. Depending on the applied method, the preva-
lence of LTBI among the study population varied consid-
erably. However, the substantially lower frequency of
positive QFT-GIT results may provide the opportunity to
target preventive therapy and thus contribute to enhanced
TB control in health care.
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